Nanomedicine News

RSS

Nanomolecular Therapy Safely Delivers TUSC2 Tumor Suppressor to Cancer Cells

Biopharmaceutical company, Genprex, reports positive results on a clinical trial conducted for Oncoprex nanoparticles to treat advanced lung cancer.

30 Apr 2012

Key Industry Figures Join Board of CRANN, Progressing Strategy for Nanoscience Commercialisation

CRANN (Centre for Research on Adaptive Nanostructures and Nanodevices), the Science Foundation Ireland funded nanoscience institute based in Trinity College Dublin (TCD), today announced the addition of three new Board m...

26 Apr 2012

Duke University Uses Nanoparticle Tracking Analysis to Characterize "Nanoconstructs" for Biomedical Applications

From Duke University - Fitzpatrick Center for Photonics 24 Apr 2012

Alnylam Reports Positive Phase I Clinical Study Results for Lipid Nanoparticle-Based ALN-PCS

According to Tekmira Pharmaceuticals, a specialist in RNA interference (RNAi) therapeutics, Alnylam Pharmaceuticals has reported positive results on its Phase I clinical study of ALN-PCS, a target-specific RNAi therapeutic for PCSK9 called ALN-PCS that uses Tekmira Pharmaceuticals’ lipid nanoparticle technology to treat severe hypercholesterolemia.

23 Apr 2012

New Nanochain Targeted Delivery System for Effective Cancer Treatment

A research team led by Efstathios Karathanasis from the Case Western Reserve University has developed a novel nanochain targeted delivery system that delivers an anti-cancer medicine into hard-to-reach areas of tumor.

20 Apr 2012

Study Reveals Smaller Nanomedicines are Ideal for Cancer Treatment

Researchers from the Massachusetts General Hospital have discovered that tumor blood vessel normalization by antiangiogenesis drugs only improves the delivery of smaller nanotherapy molecules, but blocks the supply of larger nanomedicine molecules to cancer cells.

12 Apr 2012

Nanobubble Injection Mechanism Offers New Approach for Drug and Gene Delivery

Scientists from Rice University have teamed up with the Baylor College of Medicine (BCM) and the University of Texas MD Anderson Cancer Center to study drug and gene delivery. In experimental studies, which involved drug-resistant cancer cells, the scientists discovered that when compared to conventional drug treatment, chemotherapy drugs loaded with nanobubbles were 30x more lethal to cancer cells and needed just 1/10th of the clinical dose.

11 Apr 2012